1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Peripheral Neuropathy Market
2.2. Global Peripheral Neuropathy Market, By Treatment Type, 2023 (US$ Million)
2.3. Global Peripheral Neuropathy Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Peripheral Neuropathy Market: Competitive Analysis
3.1. Market Positioning of Key Peripheral Neuropathy Market Vendors
3.2. Strategies Adopted by Peripheral Neuropathy Market Vendors
3.3. Key Industry Strategies
4. Peripheral Neuropathy Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Peripheral Neuropathy Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Pharmacological Therapies
5.3.1.1. Pain Relievers
5.3.1.1.1. Tramadol
5.3.1.1.2. Oxycodone
5.3.1.1.3. Cylcooxgenase Inhibitors
5.3.1.1.4. Corticosteroid
5.3.1.2. Anti-seizure medicationsction
5.3.1.2.1. Gabapentin
5.3.1.2.2. Pregabalin
5.3.1.3. Antidepressants
5.3.1.3.1. Amitriptyline
5.3.1.3.2. Doxepin
5.3.1.3.3. Nortriptyline
5.3.1.3.4. Duloxetine
5.3.1.3.5. Venlafaxine
5.3.1.4. Non-Pharmacological Therapies
5.3.1.4.1. Transcutaneous electrical nerve stimulation
5.3.1.4.2. Plasma exchange and intravenous immune globulin
5.3.1.4.3. Others(Physical Therapy and Surgery)


6. North America Peripheral Neuropathy Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
6.3.Peripheral Neuropathy Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)

7. UK and European Union Peripheral Neuropathy Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.Peripheral Neuropathy Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)

8. Asia Pacific Peripheral Neuropathy Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.Peripheral Neuropathy Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)

9. Latin America Peripheral Neuropathy Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
9.3.Peripheral Neuropathy Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)

10. Middle East and Africa Peripheral Neuropathy Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
10.3.Peripheral Neuropathy Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bristol Myers Squibb
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Cipla Limited
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. GlaxoSmithKline plc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Lupin Limited
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Merck and Co. Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Novartis
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Pfizer Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Dr. Reddy's Laboratories
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives